Biosimilars versus biologics for inflammatory conditions.
作者信息
Perry Danielle, Ton Joey, Kolber Michael R
机构信息
Knowledge Translation Expert with the PEER Group in the Department of Family Medicine at the University of Alberta in Edmonton.
Professor with the PEER Group in the Department of Family Medicine at the University of Alberta in Edmonton.
出版信息
Can Fam Physician. 2019 Sep;65(9):636.
Abstract
摘要
相似文献
1
Biosimilars versus biologics for inflammatory conditions.
Can Fam Physician. 2019 Sep;65(9):636.
2
Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Clin Pharmacol Ther. 2021 Mar;109(3):739-745. doi: 10.1002/cpt.2042. Epub 2020 Oct 3.
3
[Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Dtsch Med Wochenschr. 2014 Nov;139(47):2399-404. doi: 10.1055/s-0034-1387371. Epub 2014 Nov 12.
4
[Biologics and biosimilars].
Laeknabladid. 2014 May;100(5):267. doi: 10.17992/lbl.2014.05.541.
5
Biologicals and how they revolutionized rheumatology.
Wien Med Wochenschr. 2015 Jan;165(1-2):1-2. doi: 10.1007/s10354-015-0343-z.
6
Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):143-155. doi: 10.1080/17474124.2019.1553617. Epub 2019 Jan 17.
7
[Biological and biosimilar drugs: Clarifying concepts].
Aten Primaria. 2018 Jun-Jul;50(6):323-324. doi: 10.1016/j.aprim.2018.01.002. Epub 2018 Mar 28.
8
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.
9
Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S102-6. Epub 2012 Oct 18.
10
The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
J Gastroenterol Hepatol. 2019 Aug;34(8):1269-1270. doi: 10.1111/jgh.14817.
本文引用的文献
1
Prescribed Drug Spending in Canada, 2019: A Focus on Public Drug Programs.
Healthc Q. 2020 Apr;23(1):10-12. doi: 10.12927/hcq.2020.26145.
2
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Lancet. 2019 Apr 27;393(10182):1699-1707. doi: 10.1016/S0140-6736(18)32196-2. Epub 2019 Mar 28.
3
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.
RMD Open. 2018 Nov 14;4(2):e000757. doi: 10.1136/rmdopen-2018-000757. eCollection 2018.
4
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
Ann Rheum Dis. 2018 Feb;77(2):234-240. doi: 10.1136/annrheumdis-2017-211741. Epub 2017 Oct 17.
5
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Rheumatology (Oxford). 2017 Oct 1;56(10):1771-1779. doi: 10.1093/rheumatology/kex254.
6
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.
Ann Rheum Dis. 2017 Sep;76(9):1598-1602. doi: 10.1136/annrheumdis-2017-211281. Epub 2017 Jun 21.
7
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
Ann Rheum Dis. 2017 Oct;76(10):1679-1687. doi: 10.1136/annrheumdis-2016-210459. Epub 2017 Jun 5.
8
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11.
9
A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
Ann Rheum Dis. 2017 Jan;76(1):65-71. doi: 10.1136/annrheumdis-2015-207613. Epub 2016 Feb 23.
10
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
Ann Rheum Dis. 2017 Jan;76(1):58-64. doi: 10.1136/annrheumdis-2015-207764. Epub 2015 Aug 28.
Zotero 插件